In an industrialized society, the increase in obesity incidence has led to an increase in premature morbidity and mortality rates. There is a relationship between body mass index (BMI) and the increased incidence of hypertension, dyslipidemia, type 2 diabetes mellitus, and cardiovascular disease, an increase in mortality. However, obese individuals with these conditions may have better outcomes than their lean counterparts, thus the term "obesity paradox." Most studies supporting this paradox are cross-sectional and do not take into account the quantity or type of adiposity, the disease severity, and comorbidities. Although BMI is an indicator of the amount of body fat, it does not differentiate between adiposity types. Adipocytes that are highly functional have good fuel storage capacity are different from adipocytes found in visceral obesity, which are poorly functioning, laden with macrophages, and causing low-grade inflammation. Individuals with high BMI may be physically fit and have a lower mortality risk when compared with individuals with a lower BMI and poorly functioning adiposity. We review the complexity of adipose tissue and its location, function, metabolic implications, and role in cardiovascular morbidity and mortality. The terminology "obesity paradox" may reflect a lack of understanding of the complex pathophysiology of obesity and the association between adiposity and cardiovascular disease.
WHY MORE OBESITY?
The prevalence of obesity in the United States has continued to increase dramatically as in other developed industrialized societies, a trend that now appears to be leveling off. 3 The cause of the increased rate of obesity is multifactorial, driven by an interplay of genetic and environmental factors. 4 Genes have a particularly strong impact as evident by the clustering of obesity among certain families and racial groups. An individual with "genetic susceptibility" for obesity who is exposed to a "toxic environment" is more likely to gain weight and be at higher risk for premature morbidity and mortality. 4, 5 A "toxic environment" is not limited to excessive caloric intake and a sedentary lifestyle. It comprises many other variables that include geographic location (such as certain southern states known as the "obesity belt" or living in neighborhoods with higher rates of obesity), 6 socioeconomic status and education, 7 stress, 8 work schedules, air pollutants, 9 sleep habits, 10, 11 and processed foods. The rapid increase in obesity and the high incidence of T2DM affecting a younger population suggest that epigenetic changes may also have a role. These are characterized by gene expression and/or cellular phenotype caused by mechanisms other than alterations of the DNA sequence. These inheritable modifications contribute to the incessantly high incidence of obesity in a younger population. 12, 13 In addition, the excessive caloric intake in obese individuals is not well regulated by the brain. As illustrated in Figure 1 , the dysfunctional resistance to excessive fuels and hormones such as leptin and insulin prevents the expected satiety and appetite suppression, 14 leading to excessive caloric intake and weight gain. 14, 15 
IS BMI A GOOD INDICATOR OF OBESITY?
Obesity, defined as a condition of excess body fat (adiposity), is detrimental to health. 16 For adults, being overweight or obese is defined by using weight and height to calculate a statistical measurement called BMI. This prevalent method is used for population assessment of overweight and obesity and correlates with the overall body adiposity (as measured by hydrodensitometry). Because it only requires height and weight measurements, it is pragmatic, inexpensive, and commonly used. Although BMI includes consideration of body weight, it measures neither the percentage component of body fat, the type of fat, and where in the body it is located nor the degree of metabolic disturbances that it can cause. Because of this, other techniques have been used for estimating body fat and body fat distribution, such as measurements of skinfold thickness, waist circumference, waist-to-hip circumference ratio, and imaging techniques (ie, ultrasound, computed tomography, and magnetic resonance imaging). These measurements are less practical, some are expensive, and therefore are used mainly for research purposes. It is important to remember that BMI represents just one indicator of potential health risks, and other parameters are necessary to estimate CVD risk. For instance, the National Heart, Lung, and Blood Institute guidelines recommend other predictors, such as blood pressure, serum lipid levels, and/or physical activity levels. 17 Obesity does not imply good health as the majority of obese individuals have the MetSyn. In addition, obese individuals have a high incidence of comorbidities such as T2DM, CVD, and cancer, among others. Obesity is a spectrum of distinct subtypes described in the literature and summarized in Table 1 . [18] [19] [20] [21] [22] It is estimated that approximately 25% of obese individuals can be metabolically healthy, 18, 23, 24 and although they have a high BMI, they are not insulin resistant, 19 have normal lipid profiles, and in general, favorable CVD risk. 25 Alternatively, approximately 23% of the normal-weight adult population is "metabolically obese normal-weight," 24 a term coined approximately 40 years ago. 23 The "metabolically obese normalweight" population characterizes individuals with a normal BMI who are insulin resistant and have dyslipidemia, similar to unhealthy obese individuals. The dyslipidemia of obesity is characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL). These individuals tend to have lower physical activity energy expenditure and increased visceral adiposity, and are at high risk for CVD even while having a lower BMI. 24, [26] [27] [28] [29] The MetSyn is defined when at least 3 of the following criteria are present: 30 (1) waist circumference is 102 cm or greater in males and 88 cm or greater in females; (2) serum triglycerides are 150 mg/dL or greater or receiving drug treatment for elevated triglycerides; (3) serum HDL is less than 40 mg/dL in men and less than 50 mg/dL in women or receiving drug treatment for low HDL levels; (4) blood pressure is 130/85 mm Hg or greater or receiving drug treatment for hypertension; or (5) fasting blood glucose is 100 mg/dL or greater or receiving drug treatment for elevated blood glucose. Because visceral obesity may be phenotypically deceiving, an alternate set of criteria for the MetSyn is used by the International Diabetes Federation. These criteria include ethnicity-specific central or visceral obesity plus 2 other factors: (1) triglycerides greater than 150 mg/dL or receiving treatment for elevated triglycerides; (2) HDL less than 40 mg/dL in men or less than 50 mg/dL in women, or receiving treatment for low HDL; (3) blood pressure greater than 130/85 or receiving drug treatment for hypertension; FIGURE 1. Illustration of complex and multiorgan relationship between excessive nutrients and neuronal dysregulation responsible for obesity and cardiovascular disease (CVD). Excessive caloric intake, along with gut microbiota, plays a role in obesity and CVD. Visceral adiposity is characterized by an increased adipose mass and macrophages that together produce proinflammatory adipokines and cytokines adversely affecting the cardiovascular system. Increased visceral adiposity also causes hyperleptinemia and hyperinsulinemia that are poorly regulated by the brain, perpetuating increased caloric intake. Insulin resistance and the increased free fatty acid (FFA) flux cause dyslipidemia with increased very low-density lipoprotein (VLDL), triglycerides, and decreased high-density lipoprotein (HDL)-cholesterol which together with chronic low-grade inflammation results in CVD. FGF21, fibroblast growth factor 21; hS-CRP, highly sensitive C-reactive protein. or (4) fasting blood glucose greater than 100 mg/dL or previously diagnosed T2DM. 31 In summary, BMI alone is not a good indicator of CVD risk. The "bad adiposity," the MetSyn, and/or T2DM are all critical conditions that should be considered for the increased CVD morbidity and mortality rates.
ADIPOSITY-THE GOOD AND THE BAD
Elevated BMI alone may not be indicative of the type of adiposity or risk for CVD. As mentioned previously, "good adiposity" is characterized by adipocytes with an efficient fuel storage capacity, and "bad adiposity" is characterized by adipocytes that are inefficient in fuel storage and associated with inflammation. The majority of overweight and obese individuals have "bad adiposity" that plays a crucial role in the development of MetSyn, CVD, and an increased mortality rate.
The adipose tissue has complex endocrine functions and is a major source of proinflammatory and antiinflammatory adipokines, which play key roles in the related comorbidities. 32 Furthermore, adipose tissue has important structural and functional roles. For instance, epicardial fat is metabolically active and produces factors that modulate both cardiac structure and function with clinical implications. 33 The adipose tissue pool is composed of at least 2 functionally distinct types, namely white adipose tissue (WAT) and brown adipose tissue (BAT). WAT plays an important role in energy storage and in secretion of hormones and cytokines that have an impact on appetite regulation, metabolism, insulin resistance, and vascular disease. 34 WAT also serves as a thermal insulator and protects organs from mechanical damage. BAT differs in that instead of storing energy, it dissipates chemical energy by nonshivering thermogenesis. This process takes place via mitochondrial uncoupling mediated by expression of tissue-specific, mitochondrial and uncoupling protein 1 (UCP1). 34, 35 BAT is especially abundant in newborns and hibernating mammals. Until recently, it was thought to be scarce in adults, but was incidentally found in the supraclavicular and neck regions while using functional positron emission tomography. 36 Brown fat cells can also form "beige cells" or "recruitable brown fat cells." 37 The transformation of WAT to beige cells takes place through Irisin (named after Iris, the Greek messenger goddess), a membrane polypeptide produced by skeletal muscle. 38 Beige adipocytes have low basal expression of UCP1 and can respond to cyclic Adenosine monophosphate (AMP) stimulation with increased UCP1 expression. 37 Therefore, BAT and beige adipocytes are "good fat" that can burn calories and cause weight loss. Transformation of WAT to beige cells may also hold therapeutic potential in reducing obesity and improving glucose homeostasis.
The function of WAT varies by location in the body. In humans, adipose tissue can be found beneath the skin (subcutaneous adipose tissue), around internal organs (visceral or central adipose tissue), in bone marrow (yellow bone marrow), and in breast tissue. Insulin resistance and inadequate fuel storage capacity of the adipocytes cause a "spill-over" effect leading to accumulation of ectopic fat in nonadipose tissues. This aberrant fat accumulation correlates with an unhealthy constellation of abnormalities that are associated with MetSyn. 39, 40 Visceral obesity is linked to increased cytokine production, elevated free fatty acid flux, insulin resistance, and gluconeogenesis. 41 Insulin resistance and elevated free fatty acid flux in the portal system induce an inappropriate gluconeogenesis and increased levels of very low-density lipoprotein (VLDL). 41 The large VLDL pool found in insulin resistance is affected by cholesteryl ester transfer protein (CETP) promoting transfer of cholesteryl esters (CEs) from HDLs to the proatherogenic apolipoprotein B. In individuals with CETP deficiency, the increased HDL levels and decreased LDL levels result in longevity. A mirror image takes place in individuals with the MetSyn having a high CETP expression that results in high triglycerides and low HDL levels, with increased CVD disease.
Ectopic fat in liver (intrahepatic triglyceride content) is an important phenotypic marker of adverse metabolic consequences. 21, 42, 43 More recently, epicardial fat has also been used as a reliable marker of visceral adiposity. 33 Thus the type of adipocyte (WAT versus BAT), its metabolic activity, production of adipokines, and location have important clinical implications in obesity and supports the concept of healthy "good adiposity" versus unhealthy "bad adiposity."
ADIPOSE TISSUE AS AN ENDOCRINE ORGAN
Adipose tissue was recognized as a metabolically active endocrine organ soon after the discovery of leptin, 34 a hormone that modulates food intake by suppressing orexigenic neuropeptides such as agouti-related protein, neuropeptide Y, and gamma-aminobutyric acid, whereas at the same time upregulating the anorexigenic neuropeptide α-melanocyte-stimulating hormone. Leptin also serves as a barometer of adiposity levels and provides feedback to the brain. By this mechanism, among others, leptin regulates the dynamic balance between appetite and energy reserves, a function that is lost in individuals with obesity as their central nervous system (CNS) becomes leptin resistant, perpetuating a poorly regulated high caloric intake.
In addition to its CNS regulatory role, leptin has a direct beneficial effect on the heart by decreasing the accumulation of lipid intermediates, that lead to cellular dysfunction and cell death. 44 In the ischemic heart, leptin has also been found to reduce infarct size by delaying the opening of mitochondrial permeability, 45 a protective pathway proposed in reperfusion injury. 46 In contrast, leptin can cause atherogenesis via induction of endothelial dysfunction, upregulation of inflammatory mediators, and proliferation of vascular smooth muscle cells. 47 The beneficial effects may be decreased or abolished in individuals with MetSyn. Due to the multiple effects of leptin, it is difficult to dissect the role that leptin plays in CVD. Some believe that it is just a biomarker of vascular dysfunction. 48 Adiponectin is another adipokine with an important CVD impact. Although only produced by fat, adiponectin levels are inversely related to the volume of fat mass. 49 In contrast to leptin, its levels are decreased in proportion to fat mass. 50 Adiponectin, being a "good adipokine," improves insulin sensitivity through activation of AMP protein kinase in the liver and skeletal muscle, 51 and reduces hepatic gluconeogenesis. 52 It also has important antiatherogenic properties, such as modulating endothelial inflammatory responses, suppressing expression of macrophage scavenger receptors, and inducing conversion from macrophage to foam cells. 53, 54 In addition to leptin and adiponectin, fibroblast growth factor 21 (FGF21) has recently surfaced as an important metabolic hormone. It is predominantly produced by the liver and expressed in adipocytes and in the pancreas. It regulates glucose and lipid metabolism through the CNS and has favorable pleiotropic actions. FGF21 stimulates gluconeogenesis, fatty acid oxidation, and ketogenesis as an adaptive response to the fasting state, and acts as an autocrine factor in adipocytes during the fed state. It has been shown to confer benefits on insulin sensitivity, blood glucose, lipid profile, and body weight in the obese. High circulating levels of FGF21 can be found in obesity, MetSyn, T2DM, and coronary artery disease, suggesting FGF21 resistance. 55 An increased plasma FGF21 level is especially noted in obese individuals with fatty liver and can be used as a good biomarker of hepatic fat content. 56
ADIPOSE TISSUE AND INFLAMMATION
Adipose tissue is a major source of proinflammatory and antiinflammatory adipokines as depicted in Table 2 . 32 Increased adipose tissue mass and adipocyte hypertrophy lead to macrophage infiltration and inflammation. Adipocytes express a multitude of molecular receptors to which pathogens and inflammatory signals bind. Through activation of nuclear factor-κB, adipocytes induce secretion of inflammatory cytokines. 57 In addition, macrophages that are abundant in visceral adiposity act independently or synergistically with adipocytes, producing and regulating inflammatory cytokines. 32, 58, 59 The consequence is a chronic low-grade inflammation that plays an important role in the pathogenesis of insulin resistance, and is clinically detected by elevated circulating levels of highly sensitive C-reactive protein. 60 Many other proinflammatory cytokines, such as tumor necrosis factor-α and interleukin-6, among others, (Table 2) are involved in the inflammatory process and have been shown to play an important role in the pathogenesis of CVD. 61 Thus, a complex and multiorgan relationship exists in obesity consisting of excessive nutrient fuels, hyperleptinemia, hyperinsulinemia, and poor regulation by the brain, perpetuating obesity. The state of insulin resistance increases glucose levels through an inappropriate and excessive hepatic glucose production and decreased insulin-mediated peripheral glucose uptake that can eventually result in diabetes mellitus. At the same time, the insulin-resistant state contributes to the abnormal lipid profile. Furthermore, a state of chronic inflammation also plays a role in the proatherogenic process with increased CVD as depicted in Figure 1 .
GUT MICROBIOTA
Genes and environmental factors interact by modulating biologic processes and dietary elements (Fig. 1) . The gut metagenome is critical to this interaction, and changes in the microbial population can lead to alterations in normal metabolism that can potentially promote obesity, MetSyn, and T2DM. 62 Gut flora consists of approximately 100 trillion microorganism species living in the digestive tract, 63 with bacterial metabolic activities resembling those of an individual. Interaction between the genome and microbiome 64 leads to production of an array of metabolites that can affect the metabolism of both host and microbiota. 65 Obesity and diabetes mellitus are associated with an altered gut microbial composition in mice 66 and humans. 67, 68 Gut microbiota has also been found to modulate lipid metabolism and inflammation [69] [70] [71] via lipopolysaccharides and peptidoglycans with potential atherogenesis. 72 Emerging data show the importance and interdependency between gut microbiota and diseases, and remains an area of active research.
CAN THE OBESITY PARADOX BE EXPLAINED BY INCREASED BMI WITH ABSENCE OF THE METABOLIC SYNDROME?
Measurement of BMI alone does not provide information regarding the amount or type of adiposity. It is the type of adiposity, its location, function, and the resultant degree of inflammation that have deleterious consequences on cardiovascular health. Obese and nonobese individuals who are metabolically healthy have lower levels of inflammatory markers such as complement component 3, C-reactive protein, interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, and higher levels of adiponectin compared with their metabolically unhealthy counterparts. 61 Therefore, it is the amount of "bad fat," and not BMI per se that is important. 73 In a large study, a BMI of 22.5-25 kg/m 2 , the so called "sweet spot," showed a low mortality rate (Fig. 2) . Above this range, each 5 kg/m 2 increase in BMI was associated with an approximate 30% higher all-cause mortality, whereas individuals with low BMI also had increased mortality, 74 thus a "J" or "U-shaped" curve exists for BMI. Although the paradox exists in overweight and obese individuals, few studies have examined this in the more severely obese population, such as those with BMI greater than 35 kg/m 2 . These individuals do not seem to have the obesity paradox; instead they have poor outcomes and a high mortality rate. 75, 76 In fact, the morbidly obese (defined as BMI 40-45 kg/m 2 ) may have approximately 8-10 years decreased survival rate. 74 Therefore, the obesity paradox that has been described in the overweight and obese individuals does not apply to the morbidly obese. The obesity paradox exists in populations with already established CVD that are overweight or obese as measured by BMI. In these obese individuals, a higher BMI may have a protective or a less harmful effect when compared with individuals with the same chronic conditions and lower BMI [76] [77] [78] as conceptualized in Figure 2 . The paradox has also been reported in a number of epidemiological studies and meta-analyses of patients with heart failure, 79 atrial fibrillation, 80 and sudden cardiac death. 81 Decreased mortality has been noted in women with a BMI between 21 and 24 kg/m 2 and in men with a BMI between 22 and 25 kg/m 2 in men, although with important adjustments made for ethnic/racial variations. 74 As the BMI increases above these ranges, there is a higher overall mortality rate; the paradox lies in the mitigated mortality rates for individuals with higher BMI as compared with their counterparts with a lower BMI (Fig. 2) .
CLINICAL STUDIES SUPPORTING THE OBESITY PARADOX

Studies in Coronary Artery Disease
In a large prospective study involving more than 250,000 patients with CVD followed for 3.8 years, overweight and obese patients had lower mortality compared with underweight and normal weight individuals. 82 Similar findings were reported in a large crosssectional cohort of ST-elevation myocardial infarction patients, 75 and in ST-elevation myocardial infarction survivors. 83 The obesity paradox was not observed in individuals with a BMI higher than 35 kg/m 2 (morbidly obese), a population that had a high mortality rate. A U-shape curve for the relation between BMI and mortality was also found in a large Swedish study with CAD. Underweight patients (BMI <18.5 kg/m 2 ) had the highest mortality rates, followed by patients with normal weight, whereas the overweight patients (BMI 26.5-28 kg/m 2 ) had the lowest mortality. All-cause mortality decreased with increasing BMI between 30 and 40 kg/m 2 , and then began to increase again at a BMI of greater than 40 kg/m 2 . 84
Studies in Heart Failure
The mortality rate in chronic systolic heart failure is inversely related to BMI, 85 with a lower mortality risk in the overweight and obese as compared with individuals at a "healthy weight," again confirming the "obesity paradox." [86] [87] [88] Other studies support these findings with a 10% lower mortality rate for every 5 unit increase in BMI. Similar results were found in younger hospitalized individuals, with lower mortality in a near-linear manner in those with higher BMI, despite having a higher prevalence of T2DM. 89 In advanced systolic heart failure, every 1% increase in body fat resulted in a 13% independent reduction of CVD events, 90 with similar findings in other observational heart failure studies. 79 Therefore, there is evidence of a lower mortality rate with a higher BMI in individuals with heart failure.
Studies in T2DM
Several studies have described a decreased mortality rate in obese individuals with T2DM. In a pooled analysis of 5 longitudinal cohort studies, results showed that participants who were normal weight experienced higher total and noncardiovascular mortality rates compared with those who were overweight or obese. 2 All clinical studies show that patients with coronary artery disease, heart failure, and T2DM have a lower mortality with a higher BMI, thus supporting the obesity paradox. It is conceivable that patients with established diseases may garner protective effects from increased "good adiposity" or fewer harmful effects by having less "bad adiposity," the latter being more likely. The potential benefits of good adiposity have been attributed to higher fuel reserve, and/or the presence of other protective factors. [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] For instance, in heart failure, adipose tissue secretes soluble tumor necrosis factor-α receptors that neutralize the adverse biological effects of tumor necrosis factor-α. 92 Higher levels of circulating lipoproteins in obese patients can bind lipopolysaccharides, decreasing inflammatory cytokine secretion, also used as an explanation for the paradox. [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] An important potential confounder lies in the fact that obese patients may be diagnosed earlier and treated more aggressively than nonobese patients. 77 All these mechanisms supporting the obesity paradox found in clinical studies may be valid but none is well established. In fact, a true paradox may not exist at all. 94 Instead, we may simply be observing heterogeneous populations that have been poorly characterized into obese and nonobese groups by measurements of BMI alone, without factoring-in the type of adiposity, level of inflammation, and the metabolic health. 95 Furthermore, the severity of underlying illness and the comorbidities is not adjusted in most of the studies. Patients with catabolic diseases such as cancer or other terminal illness often have abnormally low body weight along with an increased mortality rate, part of the "J" or "U"-shaped mortality curve observed in epidemiological studies. When associated catabolic diseases are ruled out, a "J" curve is still seen for CVD, particularly in severe and terminal heart failure with cardiac cachexia, a wasting syndrome with significant weight loss in the absence of peripheral edema. 96 Finally, death is another confounding factor as in nonprospective epidemiological observational studies; individuals with high death rate are not part of the analysis. Thus, the obesity paradox as characterized by BMI alone, without consideration of other confounders, should not be accepted as a true paradox.
Sweet
TREATMENT
There is a growing body of evidence supporting the positive effects of physical activity and weight loss on health-related outcomes. Recent data from the Look AHEAD (Action for Health in Diabetes) study showed that obese patients with T2DM treated with standard of care medications for T2DM, hypertension, and hyperlipidemia had sustained weight loss that resulted in improved fitness and improved levels of biomarkers such as adiponectin and HDL, but CVD morbidity or mortality were not affected. 97, 98 Data from the Aerobics Center Longitudinal Study showed that lifestyle changes had a positive effect on fitness and mortality. 99, 100 Independent of corresponding changes in BMI, regular physical activity is effective for improving cardiorespiratory fitness, lipid profile, blood pressure, glucose metabolism, and visceral fat. 101, 102 Thus, regardless of the BMI, cardiorespiratory fitness lowers the metabolic risk. Certainly, weight gain cannot be recommended as a therapy to justify an obesity paradox.
CONCLUSIONS
Being overweight or obese is not healthy. There is a clear relationship between higher weight, as determined by BMI, and the increased incidence of hypertension, dyslipidemia, T2DM, CVD, and increased mortality. The obesity paradox exists in epidemiological observational studies using BMI alone as a marker for obesity, but does not distinguish individuals who may have "bad adiposity" or the MetSyn. Individuals with a higher BMI may be physically fit, with less insulin resistance, better lipid profile and therefore lower mortality. Similarly, individuals with a normal BMI and an adverse metabolic profile may have a false sense of protection from their normal weight; nonetheless, they have the MetSyn and an associated high mortality rate. Adipose tissue can have both protective and harmful effects. It is the type of adiposity that can play a role in CVD. The obesity paradox may simply reflect a lack of understanding of the complex pathophysiology of obesity and the association between adiposity and CVD.
